Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;13(3):189-198.
doi: 10.2174/1573403X13666170116121451.

The Prognostic Value of Heart Type Fatty Acid Binding Protein in Patients with Suspected Acute Coronary Syndrome: A Systematic Review

Julia D Jones  1 , Pei G Chew  1 , Rebecca Dobson  1 , Andrew Wootton  2 , Reza Ashrafi  3 , Aleem Khand  4
Affiliations

The Prognostic Value of Heart Type Fatty Acid Binding Protein in Patients with Suspected Acute Coronary Syndrome: A Systematic Review

Julia D Jones et al. Curr Cardiol Rev. 2017.

Abstract

Background: Heart type fatty acid protein (HFABP) is a cytosolic protein released early after acute coronary syndrome (ACS) even in the absence of myocardial necrosis.

Objectives: The purpose of this systematic review was to determine whether HFABP levels in patients with suspected, or confirmed ACS, improve risk stratification when added to established means of risk assessment.

Methods: We searched Medline, Pubmed and Embase databases from inception to July 2015 to identify prospective studies with suspected or confirmed ACS, who had HFABP measured during the index admission with at least 1 month follow up data. A prognostic event was defined as allcause mortality or acute myocardial infarction (AMI).

Results: 7 trials providing data on 6935 patients fulfilled inclusion criteria. There were considerable differences between studies and this was manifest in variation in prognostic impact of elevated HFABP(Odds ratio range 1.2-15.2 for death). All studies demonstrated that HFABP provide unadjusted prognostic information and in only one study this was negated after adjusting for covariates. A combination of both negative troponin and normal HFABP conferred a very low event rate. No study evaluated the incremental value of HFABP beyond that of standard risk scores. Only one study used a high sensitive troponin assay.

Conclusion: There was marked heterogeneity in prognostic impact of HFABP in ACS between studies reflecting differences in sampling times and population risk. Prospective studies of suspected ACS with early sampling of HFABP in the era of high sensitivity troponin are necessary to determine the clinical value of HFABP. HFABP should not currently be used clinically as a prognostic marker in patients with suspected ACS.

Keywords: AMI; Acute coronary syndromes; HFABP; biomarkers; prognosis; systematic review.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Flowchart: search strategy and relevant yield of studies included in systematic review.
Fig. (2)
Fig. (2)
Funnel plot of Standard error of odds ratio against odds ratio of death with elevated HFABP in [suspected] ACS (‘weighted’ point estimate of 6 studies [7, 9, 10, 12-14]).
See this image and copyright information in PMC

References

    1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 2007;50:e1–e157. - PubMed
    1. D’Ascenzo F., Biondi-Zoccai G., Moretti C., et al. TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemp. Clin. Trials. 2012;33:507–514. - PubMed
    1. Widera C., Pencina M.J., Meisner A., et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur. Heart J. 2012;33:1095–1104. - PMC - PubMed
    1. Eggers K.M., Kempf T., Venge P., Wallentin L., Wollert K.C., Lindahl B. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am. Heart J. 2010;160:88–94. - PubMed
    1. Storch J., Thumser A.E. The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta. 2000;1486:28–44. - PubMed

Publication types